2022
The Lancet. Infectious diseases, (2022).22 8 10.1016/s1473-3099(22)00374-7.
Safety of the Ad26.ZEBOV/MVA-BN-Filo vaccine regimen in adults, children and pregnant women in DRC and immunogenicity of a delayed 2nd dose: the DRC-EB-001 trial.
2022
(2022).
2022
EClinicalMedicine, (2022).50, 10.1016/j.eclinm.2022.101506.
2022
Parasite Immunology, (2022).44 9 10.1111/pim.12939.
2022
medRxiv (2022). 10.1101/2022.06.14.22276391.
2022
medRxiv (2022). 10.1101/2022.06.09.22276188.
2022
International Journal for Equity in Health, (2022).21 1 10.1186/s12939-022-01678-5.
2022
Frontiers in Public Health, (2022).10, 10.3389/fpubh.2022.897013.
2022
Expert review of vaccines, (2022).21 9 10.1080/14760584.2022.2084075.
2022
European respiratory review, (2022).31 164 10.1183/16000617.0044-2022.
